Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Juvenile | 11 | 2024 | 32 | 1.760 |
Why?
|
| Lupus Erythematosus, Systemic | 15 | 2022 | 235 | 1.260 |
Why?
|
| Granulomatosis with Polyangiitis | 4 | 2025 | 13 | 1.230 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 67 | 1.070 |
Why?
|
| Rheumatic Diseases | 3 | 2017 | 30 | 0.930 |
Why?
|
| Antirheumatic Agents | 7 | 2024 | 59 | 0.900 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 4 | 2025 | 10 | 0.750 |
Why?
|
| Microscopic Polyangiitis | 4 | 2025 | 4 | 0.750 |
Why?
|
| Rheumatology | 3 | 2022 | 39 | 0.700 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2021 | 20 | 0.680 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 25 | 0.600 |
Why?
|
| Catatonia | 1 | 2019 | 9 | 0.580 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2019 | 8 | 0.580 |
Why?
|
| Electroconvulsive Therapy | 1 | 2019 | 26 | 0.570 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 249 | 0.560 |
Why?
|
| Immunosuppressive Agents | 7 | 2025 | 987 | 0.560 |
Why?
|
| Aspirin | 1 | 2019 | 164 | 0.550 |
Why?
|
| Immunologic Factors | 1 | 2019 | 175 | 0.540 |
Why?
|
| Child | 26 | 2025 | 7273 | 0.470 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2015 | 2 | 0.450 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 94 | 0.440 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 306 | 0.430 |
Why?
|
| Adolescent | 20 | 2025 | 9550 | 0.420 |
Why?
|
| Cyclophosphamide | 4 | 2024 | 278 | 0.390 |
Why?
|
| Pyrroles | 3 | 2024 | 165 | 0.370 |
Why?
|
| Glucocorticoids | 3 | 2018 | 360 | 0.300 |
Why?
|
| Female | 27 | 2025 | 48544 | 0.250 |
Why?
|
| Humans | 38 | 2025 | 93138 | 0.240 |
Why?
|
| Rituximab | 2 | 2024 | 129 | 0.240 |
Why?
|
| Lupus Nephritis | 3 | 2018 | 78 | 0.230 |
Why?
|
| Arthralgia | 2 | 2015 | 41 | 0.220 |
Why?
|
| Mycophenolic Acid | 3 | 2022 | 85 | 0.210 |
Why?
|
| Atherosclerosis | 3 | 2013 | 254 | 0.210 |
Why?
|
| Child, Preschool | 9 | 2025 | 3781 | 0.210 |
Why?
|
| Glomerulonephritis | 1 | 2025 | 80 | 0.210 |
Why?
|
| Treatment Outcome | 11 | 2025 | 9074 | 0.210 |
Why?
|
| Piperidines | 1 | 2024 | 163 | 0.200 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 75 | 0.190 |
Why?
|
| Pharmaceutical Services | 1 | 2022 | 9 | 0.180 |
Why?
|
| Induction Chemotherapy | 2 | 2024 | 146 | 0.180 |
Why?
|
| Kidney Diseases | 1 | 2025 | 309 | 0.180 |
Why?
|
| Heptanoic Acids | 2 | 2013 | 72 | 0.180 |
Why?
|
| Pyrimidines | 1 | 2024 | 382 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2002 | 78 | 0.180 |
Why?
|
| Skin Ulcer | 1 | 2021 | 27 | 0.170 |
Why?
|
| Abatacept | 1 | 2021 | 87 | 0.160 |
Why?
|
| Pediatrics | 3 | 2017 | 378 | 0.160 |
Why?
|
| Withholding Treatment | 2 | 2019 | 121 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 59 | 0.160 |
Why?
|
| Saliva | 1 | 2001 | 124 | 0.160 |
Why?
|
| Remission Induction | 3 | 2024 | 737 | 0.160 |
Why?
|
| DNA, Viral | 1 | 2001 | 234 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 753 | 0.150 |
Why?
|
| Male | 20 | 2025 | 44357 | 0.150 |
Why?
|
| S100A12 Protein | 1 | 2019 | 10 | 0.150 |
Why?
|
| Calgranulin A | 1 | 2019 | 11 | 0.150 |
Why?
|
| Calgranulin B | 1 | 2019 | 16 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2011 | 2485 | 0.140 |
Why?
|
| Benzodiazepines | 1 | 2019 | 56 | 0.140 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2009 | 8 | 0.140 |
Why?
|
| Methotrexate | 4 | 2021 | 226 | 0.140 |
Why?
|
| Infant | 3 | 2019 | 3156 | 0.140 |
Why?
|
| Registries | 5 | 2025 | 995 | 0.130 |
Why?
|
| Prednisone | 3 | 2015 | 242 | 0.130 |
Why?
|
| Disease Progression | 5 | 2025 | 1529 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2018 | 237 | 0.120 |
Why?
|
| Nephrotic Syndrome | 1 | 2016 | 33 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2011 | 2465 | 0.110 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2015 | 15 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 204 | 0.110 |
Why?
|
| Hemorrhage | 1 | 2016 | 289 | 0.110 |
Why?
|
| Calcitonin | 1 | 2014 | 40 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2015 | 240 | 0.110 |
Why?
|
| Diphosphonates | 1 | 2014 | 36 | 0.100 |
Why?
|
| Knee Joint | 1 | 2015 | 161 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2016 | 282 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 199 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 38 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2014 | 129 | 0.090 |
Why?
|
| Bone Density | 1 | 2014 | 236 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 557 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 430 | 0.090 |
Why?
|
| Vitamin D | 1 | 2014 | 272 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 619 | 0.090 |
Why?
|
| Risk Factors | 7 | 2023 | 5901 | 0.090 |
Why?
|
| Biomarkers | 3 | 2019 | 1905 | 0.090 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 85 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 106 | 0.080 |
Why?
|
| Intracranial Aneurysm | 1 | 2013 | 201 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2024 | 3044 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 1910 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 154 | 0.080 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2022 | 23 | 0.080 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 10 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 27 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 393 | 0.070 |
Why?
|
| Tunica Intima | 1 | 2009 | 61 | 0.070 |
Why?
|
| Symptom Flare Up | 2 | 2019 | 12 | 0.070 |
Why?
|
| Age of Onset | 2 | 2024 | 341 | 0.070 |
Why?
|
| Selenoprotein P | 1 | 2007 | 1 | 0.070 |
Why?
|
| Musculoskeletal Diseases | 1 | 2008 | 36 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2011 | 1353 | 0.060 |
Why?
|
| Kidney | 2 | 2025 | 1093 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2018 | 4546 | 0.060 |
Why?
|
| Proteoglycans | 1 | 1986 | 75 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 691 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 688 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1416 | 0.050 |
Why?
|
| Neutrophils | 1 | 1986 | 324 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2024 | 25 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 752 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 282 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1727 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2023 | 59 | 0.050 |
Why?
|
| Azathioprine | 2 | 2016 | 122 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2337 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2013 | 39 | 0.050 |
Why?
|
| Young Adult | 4 | 2022 | 6922 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 170 | 0.040 |
Why?
|
| Neoplasms | 1 | 2017 | 3169 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 120 | 0.040 |
Why?
|
| Logistic Models | 1 | 2025 | 1241 | 0.040 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2000 | 17 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2001 | 41 | 0.040 |
Why?
|
| Health Status | 1 | 2003 | 373 | 0.040 |
Why?
|
| Time Factors | 3 | 2019 | 5379 | 0.040 |
Why?
|
| Sex Factors | 2 | 2017 | 1102 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 603 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2023 | 712 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 289 | 0.040 |
Why?
|
| Quality of Life | 1 | 2008 | 1776 | 0.040 |
Why?
|
| Echocardiography | 1 | 2023 | 748 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 320 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 888 | 0.040 |
Why?
|
| Life Tables | 1 | 2018 | 46 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2000 | 331 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 91 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1519 | 0.030 |
Why?
|
| Rheumatologists | 1 | 2017 | 7 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2787 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2018 | 913 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1849 | 0.030 |
Why?
|
| Haplotypes | 2 | 2009 | 647 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2016 | 26 | 0.030 |
Why?
|
| Bayes Theorem | 2 | 2009 | 403 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 366 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 245 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 108 | 0.030 |
Why?
|
| United States | 3 | 2016 | 7581 | 0.030 |
Why?
|
| Proteinuria | 1 | 2016 | 69 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 753 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 163 | 0.030 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 67 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 194 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 206 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 889 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 338 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 1866 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 51 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 109 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1003 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2014 | 278 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2016 | 349 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2014 | 167 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 1698 | 0.020 |
Why?
|
| Puberty | 1 | 2013 | 54 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2013 | 292 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2011 | 10 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2013 | 130 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2011 | 47 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 246 | 0.020 |
Why?
|
| California | 1 | 2011 | 157 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 167 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 272 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 750 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2010 | 28 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 83 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 91 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3815 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 205 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 277 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 296 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 231 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 502 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 10132 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2009 | 59 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2009 | 136 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 364 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1896 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1994 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 293 | 0.020 |
Why?
|
| Microchip Analytical Procedures | 1 | 2007 | 3 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1526 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 276 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 2889 | 0.020 |
Why?
|
| Zymosan | 1 | 1986 | 2 | 0.020 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 1986 | 4 | 0.020 |
Why?
|
| Glycosides | 1 | 1986 | 12 | 0.020 |
Why?
|
| Sulfates | 1 | 1986 | 38 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1986 | 73 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 679 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2007 | 478 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2009 | 806 | 0.010 |
Why?
|
| Leukocytes | 1 | 1986 | 210 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1578 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1926 | 0.010 |
Why?
|
| Computational Biology | 1 | 2007 | 581 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1986 | 284 | 0.010 |
Why?
|
| Joints | 1 | 2003 | 32 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 2003 | 32 | 0.010 |
Why?
|
| Uveitis | 1 | 2003 | 35 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 2545 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 195 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 210 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1986 | 2827 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1763 | 0.010 |
Why?
|
| Adult | 1 | 2001 | 27850 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 36 | 0.010 |
Why?
|
| Celecoxib | 1 | 2000 | 33 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 99 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2000 | 271 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2000 | 152 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 12224 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 1260 | 0.010 |
Why?
|
| Arthrography | 1 | 1993 | 6 | 0.010 |
Why?
|
| Carpal Bones | 1 | 1993 | 12 | 0.010 |
Why?
|
| Wrist Joint | 1 | 1993 | 24 | 0.010 |
Why?
|
| Movement | 1 | 1993 | 307 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 27965 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 181 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1989 | 400 | 0.000 |
Why?
|